Loading
Life sciences · Review
Sciences of Pharmacy · November 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Solid lipid nanoparticles (SLNs) have been investigated as lipid-based delivery systems to improve the solubility, stability, bioavailability, and delivery of plant-derived phytochemicals to tumors for cancer therapy. However, the available evidence remains heterogeneous and predominantly preclinical. This systematic review aimed to evaluate the formulation strategies, physicochemical characteristics, and therapeutic applications of phytochemical-loaded SLNs in cancer therapy. The review followed the PRISMA 2020 guidelines. Original research articles in English investigating phytochemical-loaded SLNs for cancer therapy were included. Data on formulation composition, preparation methods, physicochemical properties, drug release, in vitro anticancer activity, pharmacokinetics, biodistribution, and in vivo antitumor efficacy were extracted. Risk of bias was assessed using the SYRCLE tool for animal studies and an adapted checklist for in vitro studies. Thirty one articles were included in the qualitative synthesis. Most SLNs had particle sizes in the nanoscale range, approximately 50-350 nm, with encapsulation efficiencies of 43-99% and sustained-release profiles. Encapsulation generally improved cellular uptake and in vitro cytotoxicity in several cancer models. However, evidence of improved bioavailability, active tumor targeting, and in vivo antitumor efficacy remained limited and heterogeneous. Surface modification enhanced cellular uptake or organ accumulation in some studies, but validated tumor-specific targeting was not consistently demonstrated. Overall, phytochemical-loaded SLNs demonstrate potential as delivery platforms; however, clinical translation requires standardized formulations, robust in vivo studies, comprehensive safety evaluations, and clinical trials.